Daniel Auclair

The paper identifies genomic subtypes of multiple myeloma using the MMRF CoMMpass study and finds that 25.5% of patients transition to a high-risk expression subtype at progression, which expresses immunotherapy targets.

This study identifies 100 SV hotspots and 31 new candidate driver genes in multiple myeloma, revealing that 63% of SVs remain unexplained and are associated with outlier gene expression.

The paper identifies IgL translocations in multiple myeloma as a marker of poor prognosis, often misclassified as standard risk due to co-occurrence with hyperdiploidy.